Skip to main content
SpringerLink
Log in

Fluoroquinolones in urinary tract infection

  • Chapter
  • First Online:
Fluoroquinolone Antibiotics

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

Urinary tract infection (UTI) is one of the most common infectious diseases for which antibiotic therapy is prescribed. Many characteristics of the fluoroquinolones make them ideal agents for the management of UTI [1-12]. As a class, the fluoroquinolones traditionally have been highly active in vitro against nearly all significant urinary pathogens. Most are renally excreted, hence achieve high concentrations in the urine. They penetrate the prostrate well. Their high oral bioavailability allows oral therapy for infections that traditionally would be treated with intravenous antibiotics, and their long half-lives allow convenient once-or twice-daily dosing. The currently marketed fluoroquinolones have favorable adverse effect profiles and few significant drug-drug interactions. Consequently, fluoroquinolones have been and probably will continue to be used extensively in the treatment and prevention of UTI in a wide variety of clinical contexts, as reviewed below. To what extent emerging drug resistance will compromise the utility of fluoroquinolones for UTI therapy in coming years remains to be seen, but is a significant concern.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Naber KG (1989) Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis 11 (suppl 5): S1321—S1327

    Google Scholar 

  2. Naber KG (1993) Role of quinolones in treatment of chronic bacterial prostatitis In: DC Hooper, JS Wolfson (eds): Quinolone antimicrobial agents (2nd ed.). Washington, DC, American Society for Microbiology, 285–297

    Google Scholar 

  3. Sable CA, Scheid WM (1993) Fluoroquinolones: how to use (but not overuse) these antibiotics. Geriatrics 48: 41–51

    CAS  PubMed  Google Scholar 

  4. Blondeau JM (2001) Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. Expert Opin Invest Drugs 10: 213–237

    CAS  Google Scholar 

  5. Martin SJ, Jung R, Garvin CG (2001) A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. Drug Safety 24: 199–222

    CAS  PubMed  Google Scholar 

  6. Blondeau JM (2000) A review of clinical trials with fluoroquinolones with an emphasis on new agents. Expert Opin Invest Drugs 9: 383–413

    CAS  Google Scholar 

  7. Cunha BA (1994) The fluoroquinolones for urinary tract infections: a review. Adv Ther 11: 277–296

    CAS  PubMed  Google Scholar 

  8. Hooton TM, Stamm WE (1997) Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 11: 551–582

    CAS  PubMed  Google Scholar 

  9. Stamm WE, Hooton TM (1993) Management of urinary tract infections in adults. N Engl J Med 329: 1328–1334

    CAS  PubMed  Google Scholar 

  10. Van Wijk JAE, de Jon TPVM, Vanbool JD (1992) Using quinolones in urinary tract infections in children. Adv Antimicrob Antineopl Chemother 11 (suppl. 2): 157–161

    Google Scholar 

  11. Langtry HD (1998) Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 56: 487–515

    CAS  PubMed  Google Scholar 

  12. Naber KG (2001) Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicmb Agents 17: 331–341

    CAS  Google Scholar 

  13. Ronald AR, Harding GKM (1997) Complicated urinary tract infections. Infect Dis Clin North Am 11: 583–592

    CAS  PubMed  Google Scholar 

  14. Preheim LC (1985) Complicated urinary tract infections. Am J Med 79: 62–66

    CAS  PubMed  Google Scholar 

  15. Foxman B, Barlow R, D’Arcy H, Gillespie B, Sobel JD (2000) Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 10: 509–515

    CAS  PubMed  Google Scholar 

  16. Stull TL, Li Puma JL (1991) Epidemiology and natural history of urinary tract infections in children. Med Clin North Am 75: 287–298

    CAS  PubMed  Google Scholar 

  17. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaffer AJ, Stamm WE (1999) Guidelines for antimicrobial therapy of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 29: 745–758

    CAS  PubMed  Google Scholar 

  18. Del Rio G, Dalet F, Aguilar L, Caffaratti J, Dalre R (1996) Single-dose rufloxacin versus three day norfloxacin treatment of uncomplicated cystitis. Antimicrob Agents Chemother 40: 408–412

    PubMed  PubMed Central  Google Scholar 

  19. Jardin A, Cesana M (1995) French Multicenter Urinary Tract Infection — Rufloxacin Group. Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. Antimicrob Agents Chemother 39: 215–220

    CAS  PubMed  PubMed Central  Google Scholar 

  20. van Balen FA, Touw-Otten FW, de Melker RA (1990) Single-dose pefloxacin versus five-days treatment with norfloxacin in uncomplicated cystitis in women. J Antimicrob Agents Chemother 6: 153–1660

    Google Scholar 

  21. Neringer R, Forsgren A, Hansson C, Ode B (1992) South Swedish Lolex Study Group. Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. Scand J Infect Dis 24: 773–780

    CAS  PubMed  Google Scholar 

  22. Nicolle LE, Dubois J, Martel AY, Harding GKM, Shafran SD, Conly JM (1995) Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. Antimicrob Agents Chemother 37: 574–579

    Google Scholar 

  23. Gupta K, Hooton TM, Roberts PL, Stamm WE (2001) Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 135: 9–16

    CAS  PubMed  Google Scholar 

  24. Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM (1999) A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 43 (suppl A): 67–75

    CAS  PubMed  Google Scholar 

  25. McCarty JM, Richard G, Huck W et al (1999) A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am J Med 106: 292–299

    CAS  PubMed  Google Scholar 

  26. Schaeffer AJ, Stuppy BA (1999) Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol 161: 207–211

    CAS  PubMed  Google Scholar 

  27. Henry DC, Nenad RC, Iravani A et al (1999) Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group. Clin Ther 21: 966–981

    CAS  PubMed  Google Scholar 

  28. Henry DC, Ellison W, Sullivan J et al (1998) Treatment of community-acquired uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. Antimicrob Agents Chemother 42: 2262–2266

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Gupta K, Hooton TM, Stamm WE (2001) Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 135: 41–50

    CAS  PubMed  Google Scholar 

  30. Masterton RG, Bochsler JA (1995) High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother 35: 129–137

    CAS  PubMed  Google Scholar 

  31. Raz R, Chazan B, Kennes Y et al (2002) Empiric use of trimethoprim-sulfamethoxazole (TMPSMZ) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMZ-resistant uropathogens. Clin Infect Dis 34(9): 1165–1169

    CAS  PubMed  Google Scholar 

  32. Le TP, Miller LG (2001) Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis 33: 615–621

    CAS  PubMed  Google Scholar 

  33. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG (1999) Factors associated with trimethoprim-resistant bacteria isolated from urine samples. JAntimicrob Chemother 43: 841–843

    CAS  Google Scholar 

  34. Wright SW, Wrenn KD, Haynes JL (1999) Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J Gen Intern Med 14: 606–609

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Sotto A, de Boever CM, Fabbro-Peray P, Gouby A, Sirot D, Jourdan J (2001) Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol 39: 438–444

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Gupta K, Scholes D, Stamm WE (1999) Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 281: 736–738

    CAS  PubMed  Google Scholar 

  37. Gupta K, Sahm DF, Mayfield D, Stamm WE (2001) Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 33: 89–94

    CAS  PubMed  Google Scholar 

  38. Enne VI, Livermore DM, Stephens P, Hall LCM (2001) Persistence of sulphonamide resistance in Escherichia coil in the UK despite national prescribing restriction. Lancet 357: 1325–1328

    CAS  PubMed  Google Scholar 

  39. Young H-K, Jesudason MV, Koshi G, Amyes SGB (1986) Trimethoprim resistance amongst urinary pathogens in South India. J Antimicrob Chemother 17: 615–621

    CAS  PubMed  Google Scholar 

  40. Andrasevic AT, Tambic T, Kalenic S, Jankovid V (2002) The Working Group of the Croatian Committee for Antibiotic Resistance Surveillance. Surveillance for antimicrobial resistance in Croatia. Emerg Infect Dis 8: 14–18

    Google Scholar 

  41. Felmingham D, Arakawa S (2001) Resistance among urinary tract pathogens. Experience outside the USA. Clin Drug Invest 21 (suppl 1): 7–11

    Google Scholar 

  42. Kahlmeter G (2000) The ECO-SENS project: a prospective, multinational, multicenter epidemio-logical survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. JAntimicrob Chemother 46 (suppl Si): 15–22

    CAS  Google Scholar 

  43. Murray BE, Alvarado T, Kim KH et al (1985) Increasing resistance to trimethoprim-sulfamethoxazole among isolates of Escherichia coli in developing countries. J Infect Dis 152: 1107–1113

    CAS  PubMed  Google Scholar 

  44. Karlowsky JA, Jones JE, Thornsberry C, Critchley I, Kelly LJ, Sahm DF (2001) Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999. Int J Antimicrob Agents 18: 121–127

    CAS  PubMed  Google Scholar 

  45. Talan DA, Stamm WE, Hooton TM et al (2000) Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women. JAMA 283: 1583–1590

    CAS  PubMed  Google Scholar 

  46. Moribelli G, Pezzoli R, Pinoja-Lutz G, Monotti R, Marone C, Franciolli M (1999) Oral versus intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med 159: 53–58

    Google Scholar 

  47. Dydek CJ, Souney PF, Matthews SJ (1992) DUE of ciprofloxacin in the treatment of urinay tract infections in hospitalized patients. Hosp Formulary 27: 185–191

    CAS  Google Scholar 

  48. Lipsky BA (1989) Urinary tract infections in men: epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med 110: 138–150

    CAS  PubMed  Google Scholar 

  49. Lipsky BA (1999) Prostatitis and urinary tract infection in men: what’s new; what’s true? Am J Med 106: 327–334

    CAS  Google Scholar 

  50. Schaeffer AJ (1987) Multiclinic study of norfloxacin for treatment of urinary tract infections. Am J Med 82 (suppl 6B): 53–58

    CAS  PubMed  Google Scholar 

  51. Ulleryd P, Zackrisson B, Aus G, Bergdahl S, Hugosson J, Sandberg T (1999) Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. B J U International 84: 470–474

    CAS  Google Scholar 

  52. Nickel JC, Downey J, Johnston B, Clark J, Group TC, (2001) The Canadian Prostatitis Research Group. Predictors of patient response to antibiotic therapy for the chronic prostatis/pelvic pain syndrome: a prospective multicenter clinical trial. J Urol 165: 1539–1544

    CAS  PubMed  Google Scholar 

  53. Falagas ME (1995) Practice guidelines: prostatitis, epididymitis, and urethritis. Infect Dis Clin Pract 4: 325–333

    Google Scholar 

  54. Pewitt EB, Schaeffer AJ (1997) Urinary tract infection in urology, including acute and chronic prostatitis. Infect Dis Clin North Am 11: 623–646

    CAS  PubMed  Google Scholar 

  55. Falagas ME, Gorbach SL (1995) Practice guidelines: urinary tract infections. Infect Dis Clin Pract 4: 241–257

    Google Scholar 

  56. Ingham B (1977) Arthropathy induced by antibacterial fused n-alkyl-4-pyridone-3carboxylic acids. Toxicol Lett 1:21–26

    CAS  Google Scholar 

  57. Schluter G (1986) Toxicology of ciprofloxacin [Abstract First International Ciprofloxacin Workshop, Proceedings (Amsterdam). Exerpta Medica 61–70

    Google Scholar 

  58. Amacher DE, Schomaker SJ, Gootz TD, McGuirk PR (1989) Proteoglycan and procollagen synthesis in rat embryo limb bud cultures treated with quinolone antibacterials. Altern Methods Toxicol 7: 307–312

    CAS  Google Scholar 

  59. Johnson CE (1999) New advances in childhood urinary tract infections. Pediatr Rev 20: 335–342

    CAS  PubMed  Google Scholar 

  60. Fanos VC, L (2000) Fluoroquinolones in pediatrics and their nephrotoxicity in adults: minireview. J Chemother 12: 228–231

    CAS  PubMed  Google Scholar 

  61. Ogle JW (1999) Antimicrobial therapy for ambulatory pediatrics. Pediair Ann 28: 434–444

    CAS  Google Scholar 

  62. Redmond AO (1997) Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom. Pediatr Infect Dis J 16: 147–149

    CAS  PubMed  Google Scholar 

  63. Hampel B, Hullmann R, Schmidt H (1997) Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use — safety report. Pediatr Infect Dis J 16: 160–162

    Google Scholar 

  64. Schaad UB (1992) Role of the new quinolones in pediatric practice. Pediatr Infect Dis J 11: 1043–1046

    CAS  PubMed  Google Scholar 

  65. Green SD (1996) Indications and restrictions of fluoroquinolone use in children. Br J Hosp Med 56: 420–423

    CAS  PubMed  Google Scholar 

  66. Fujii R, Meguro H, Arimasu O et al (1990) Evaluation of norfloxacin in the pediatric field. Pediatric Study Group for Norfloxacin. Jpn JAntibiot 43: 181–215

    CAS  Google Scholar 

  67. Ronald AR, Nicolle LE, Stamm WE et al (2001) Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents 17: 343–348

    CAS  PubMed  Google Scholar 

  68. Ronald AR, Nicolle LE, Harding GK (1992) Standards of therapy for urinary tract infections in adults. Infection 20 (suppl 3): S164–S170

    PubMed  Google Scholar 

  69. Johnson JR, Stamm WE (1989) Urinary tract infections in women: diagnosis and treatment. Ann Intern Med 111: 906–917

    CAS  PubMed  Google Scholar 

  70. Peng MY (1999) Randomized, double-blind, comparative study of levofloxacin and ofloxacin in the treatment of complicated urinary tract infections. J Microbiol Immunol Infect 32: 33–39

    CAS  PubMed  Google Scholar 

  71. Klimberg IW, Cox CEn Fowler CL, King W, Kim SS, Callery-D’Amico S (1998) A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urol 51: 610–615

    CAS  PubMed  Google Scholar 

  72. Raz R, g NK, Raizenberg C et al (2000) Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women. Eur J Clin Microbiol Infect Dis 19: 327–331

    CAS  PubMed  Google Scholar 

  73. Naber KG, Hollauer K, Kirchbauer D, Witte W (2000) In vitro activity of gatifloxacin compared with gemioxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections. Int J Antimicrob Agents 16: 239–243

    CAS  PubMed  Google Scholar 

  74. Krcmery S, Naber KG (1999) Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. German Ciprofloxacin UTI Study Group. Int J Antimicrob Agents 11: 133–138

    CAS  PubMed  Google Scholar 

  75. Naber KG, Theuretzbacher U, Moneva-Koucheva G, Stass H (1999) Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 18: 783–789

    CAS  PubMed  Google Scholar 

  76. Nicolle LE, Harding GKM, Thompson M, Kennedy J, Urias B, Ronald AR (1989) Prospective, randomized, placebo-controlled trial of norfloxacin for the prophylaxis of recurrent urinary tract infection in women. Antimicrob Agents Chemother 33: 1032–1035

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Raz R, Boger S (1991) Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection. Antimicrob Agents Chemother 35: 1241–1242

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Pfau A, Sacks TG (1994) Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women. J Urol 152: 136–138

    CAS  PubMed  Google Scholar 

  79. Krcmery S, Hromec J, Tvrdikova M, Hassan M, Gulla D (1999) Newer quinolones in the longterm prophylaxis of recurrent urinary tract infections (UTI). Drugs 58 (Suppl 2): 99–102

    CAS  PubMed  Google Scholar 

  80. Wong ES, McKevitt M, Running K, Counts GW, Turck M, Stamm WE (1985) Management of recurrent urinary tract infections with patient-administered single-dose therapy. Ann Intern Med 102: 302–307

    CAS  PubMed  Google Scholar 

  81. Biering-Sorensen F, Hoiby N, Nordenbo A, Ravnborg M, Bruun B, Rahm V (1994) Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. J Urology 151: 105–108

    CAS  Google Scholar 

  82. van der Wall E (1992) Prophylactic ciprofloxacin for catheter-associated urinary-tract infection. Lancet 339: 946–951

    PubMed  Google Scholar 

  83. Sheehan GJ, Harding GKM, Haase DA et al (1988) Double-blind randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection. Antimicrob Agents Chemother 32: 1292–1293

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Cardenas DD, Hooton TM (1995) Urinary tract infection in persons with spinal cord injury. Arch Phys Med Rehabil 76: 272–280

    CAS  PubMed  Google Scholar 

  85. Warren JW (1997) Catheter-associated urinary tract infections. Infect Dis Clin North Am 11: 609–622

    CAS  PubMed  Google Scholar 

  86. Warren J, Bakke A Desgranchamps F et al (2001) Catheter-associated bacteriuria and the role of biomaterial in prevention. In: KG Naber, JC Pechere, J Kumazawa, S Khoury, JL Gerberding, AJ Schaeffer (eds): Nosocomial and health care associated infections in urology. Health Publication Ltd., Plymouth, UK, 151–176

    Google Scholar 

  87. Bloch R (2000) Review: antimicrobial prophylaxis reduces asymptomatic bacteriuria in patients with neurogenic bladder. ACP J Club 4: 21

    Google Scholar 

  88. Lightner DJ (1998) Contemporary urologic management of patients with spinal cord injury. Mayo Clin Proc 73: 434–438

    CAS  PubMed  Google Scholar 

  89. Janoff DM, Skarecky DW, McLaren CE, Ahlering TE (2000) Prostate needle biopsy infection after four or six dose ciprofloxacin. Can J Urol 7: 1066–1069

    CAS  PubMed  Google Scholar 

  90. Christiane AP, Hollowell CM, Kim H et al (2000) Double-blind randomized comparison of single-dose ciprofloxacin versus intravenous cefazolin in patients undergoing outpatient endourologic surgery. Urol 55: 182–185

    Google Scholar 

  91. Shandera KC, Thibault GP, Deshon GEJ (1998) Efficacy of one dose fluoroquinolone before prostate biopsy. Urol 52: 641–643

    CAS  PubMed  Google Scholar 

  92. Isen K, Kupeli B, Sinik Z, Sozen S, Bozkirli I (1999) Antibiotic prophylaxis for transrectal biopsy of the prostate: a prospective randomized study of the prophylactic use of single dose oral fluoroquinolone versus trimethoprim-sulfamethoxazole. Int Urol Nephrol 31: 491–495

    CAS  PubMed  Google Scholar 

  93. Aron M, Rajeev TP, Gupta NP (2000) Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU International 85: 682–685

    CAS  PubMed  Google Scholar 

  94. Klimberg IW, Malek GH, Cox CE et al (1999) Single-dose oral ciprofloxacin compared with cefotaxime and placebo for prophylaxis during transurethral surgery. JAntimicrob Chemother 43 (suppl A): 77–84

    CAS  Google Scholar 

  95. Tsugawa M, Monden K, Nasu Y, Kumon H, Ohmori H (1998) Prospective randomized comparative study of antibiotic prophylaxis in urethrocystoscopy and urethrocystography. Int J Urol 5: 441–443

    CAS  PubMed  Google Scholar 

  96. Sahm DF, Critchley IA, Kelly LJ et al (2001) Evaluation of current activities of fluoroquinolones against Gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob Agents Chemother 45: 267–274

    CAS  PubMed  PubMed Central  Google Scholar 

  97. Gales AC, Jones RN, Gordon KA et al (2000) Activity, spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRYAntimicrobial Surveillance Program (1998) J Antimicrob Chemother 45: 295–303

    CAS  PubMed  Google Scholar 

  98. Garau J, Xercavins M, Rodriguez-Carballeira M et al (1999) Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 43: 2736–2741

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Perez-Trallero E, Urbeita M, Jimenez D, Garcia-Arenzana JM, Cilla G (1993) Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur J Clin Microbiol Infect Dis 12: 349–351

    CAS  PubMed  Google Scholar 

  100. Mirelis B, Miro E, Navarro F, Ogalla CA, Bonal J, Prats G (1993) Increased resistance to quinolones in Catalonia, Spain. Diagn Microbiol Infect Dis 16: 137–139

    CAS  PubMed  Google Scholar 

  101. Cheong H-J, Yoo C-W, Sohn J-W, Kim W-J, Kim M-J, Park S-C (2001) Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 33: 48–53

    CAS  PubMed  Google Scholar 

  102. van Belkum A, Glessens W, van der Schee C et al (2001) Rapid emergence of ciprofloxacinresistant enterobacteriaceae containing multiple gentamicin resistance-associated integrons in a Dutch hospital. Emerg Infect Dis 7: 862–871

    PubMed  PubMed Central  Google Scholar 

  103. Hsueh P-R, Liu C-Y, Luh K-T (2002) Current status of antimicrobial resistance in Taiwan. Emerg Infect Dis 8: 132–137

    PubMed  PubMed Central  Google Scholar 

  104. Gales A, KAG, Wilke W, Pfaller M, Jones R (2000) Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. Diagn Microbiol Infect Dis 36

    Article  Google Scholar 

  105. Sannes MR, San Roman M, Moya T et al (2003) Antimicrobial resistance among Escherichia coli causing urinary tract infections in Costa Rica: a clinical dilemma. Int J Antimicrob Agents 21: 79–82

    PubMed  Google Scholar 

  106. Bartlett JG, Breiman RF, Mandell LA, File TM (1998) Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 26: 811–838

    CAS  PubMed  Google Scholar 

  107. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH (2000) The Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 31: 383–421

    CAS  Google Scholar 

  108. Drugs and vaccines against biological weapons. Med Lett Drugs Ther 43: 87–89

    Google Scholar 

  109. Burke JP (1998) Antibiotic resistance — squeezing the balloon? JAMA 280: 1270–1271

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. VA Medical Center and Department of Medicine, University of Minnesota, Minneapolis, MN, USA

    James R. Johnson

Authors
  1. James R. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Faculty of Medicine, The University of Manitoba, 409 Tacho Avenue, Winnipeg, Manitoba, R2H 2A6, Canada

    Allan R. Ronald

  2. Microbiology Laboratory, Mt. Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5, Canada

    Donald E. Low

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Basel AG

About this chapter

Cite this chapter

Johnson, J.R. (2003). Fluoroquinolones in urinary tract infection. In: Ronald, A.R., Low, D.E. (eds) Fluoroquinolone Antibiotics. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8103-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8103-6_6

  • Published:

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9437-1

  • Online ISBN: 978-3-0348-8103-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation